Patents Examined by David Romeo
  • Use of TGF-? antagonists to treat infants at risk of developing bronchopulmonary dysplasia
    Patent number: 8642034
    Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: February 4, 2014
    Assignee: Genzyme Corporation
    Inventors: James B. Streisand, Jesse D. Roberts, Jr.
  • Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
    Patent number: 8637030
    Abstract: The present invention provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a S-100 protein, b) an activated-potentiated form of an antibody to histamine, and c) an activated-potentiated form of an antibody to TNF-alpha. Various embodiments and variants are provided. The present invention further provides a method of treating a disease or condition of functional etiology of the gastrointestinal tract, said method comprising administering to a patient in need thereof a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a histamine, b) an activated-potentiated form of an antibody to S-100 protein and c) an activated-potentiated form of an antibody to TNF-alpha. Various embodiments and variants are provided.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: January 28, 2014
    Inventor: Oleg Iliich Epshtein
  • FGF-9 and its use relating to blood vessels
    Patent number: 8623820
    Abstract: There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising administering an effective amount of a composition comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: January 7, 2014
    Assignee: University of Western Ontario
    Inventors: J. Geoffrey Pickering, Zengxuan Nong, Matthew Frontini
  • Antibody formulation
    Patent number: 8623367
    Abstract: The present invention relates to novel pharmaceutical formulations, in particular novel pharmaceutical formulations in which the active ingredient comprises human antibodies to human interleukin I beta (IL-1?), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: January 7, 2014
    Assignee: Novartis AG
    Inventors: Joachim Momm, Hans-Joachim Wallny
  • Anti-TNF antibodies, compositions, methods and uses
    Patent number: 8603778
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: December 10, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
    Patent number: 8597646
    Abstract: The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: December 3, 2013
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Daniel P. Judge, Enid R. Neptune, Ronald Cohn, Jennifer Habashi
  • Antibodies to TGF-?
    Patent number: 8591901
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 26, 2013
    Assignees: Genzyme Corporation, Optein, Inc
    Inventors: Steven R Ledbetter, Celia P Hart, Robert G Holgate, Lutz U Jermutus, Catriona L Buchanan, Alexander R Duncan, Donna K Finch
  • Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
    Patent number: 8586052
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: November 19, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Receptor activator of NF-kappaB
    Patent number: 8569456
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: October 29, 2013
    Assignee: Immunex Corporation
    Inventors: Dirk M Anderson, Laurent Galibert, Eugene Maraskovsky
  • Compositions and methods for increasing muscle growth
    Patent number: 8551482
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: October 8, 2013
    Assignee: Novartis AG
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
  • Methods for treating diabetic foot ulcers
    Patent number: 8536231
    Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: September 17, 2013
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Ejection liquid, ejection method, method of making droplets from liquid, cartridge and ejection device
    Patent number: 8530412
    Abstract: The present invention provides a liquid composition, as an ejection liquid used for stably ejecting liquid droplets, including at least one kind of a protein and a peptide, and a compound having a betaine skeleton by application of thermal energy to the liquid; a method of making droplets form the liquid; and an ejection method and an ejection device suitable for utilizing protein liquid droplets. By adding a compound having a betaine skeleton to an aqueous solution of at least one kind of a protein and a peptide, the liquid composition is improved in stability for ejection by application of thermal energy. Further, a surfactant may be further added to the liquid composition containing the compound having a betaine skeleton, and in this case the effect of stable ejection can be obtained.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: September 10, 2013
    Assignee: Canon Kabushiki Kaisha
    Inventors: Masaru Sugita, Yohei Masada, Hideki Kaneko
  • Methods for administering FGF18
    Patent number: 8507430
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: August 13, 2013
    Assignee: ZymoGenetics, Inc.
    Inventor: Jeff L. Ellsworth
  • Immobilized tumor necrosis factor-? muteins for enhancing immune response in mammals
    Patent number: 8501918
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: August 6, 2013
    Assignee: Cytologic, Inc.
    Inventor: Mark Douglas Howell
  • KLK-13 antibody inhibitor for treating dry eye
    Patent number: 8491905
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: July 23, 2013
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
  • Method for diagnosing and treating emphysema
    Patent number: 8486405
    Abstract: The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: July 16, 2013
    Assignee: Indiana University Research and Technology Corp.
    Inventors: Matthias Clauss, Irina Petrache, Robert Voswinckel
  • Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
    Patent number: 8449888
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: May 28, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Sustained release composition containing SDF-1
    Patent number: 8435953
    Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: May 7, 2013
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventor: Yasuhiko Tabata
  • FGF modulation of in vivo antibody production and humoral immunity
    Patent number: 8435525
    Abstract: The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.
    Type: Grant
    Filed: November 7, 2010
    Date of Patent: May 7, 2013
    Inventor: Andrew B. Bush
  • CD38 and obesity
    Patent number: 8431131
    Abstract: This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: April 30, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eduardo N. Chini, Maria Thereza P. Barbosa, Sandra M. Soares Herrmann